Cure My Disease

Don't miss your cure!

 Log in / Sign up

Exercise program tested for rare heart condition

NCT ID NCT06096675

Recruiting now Symptom relief Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests whether a supervised cardiac rehabilitation program is feasible and beneficial for people with cardiac amyloidosis, a condition where abnormal protein builds up in the heart. Participants attend three one-hour exercise sessions per week for 12 weeks. The study measures how many complete the program and whether their cardiorespiratory fitness improves.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
supervised cardiac rehabilitation sessions (exercise training)
What this could lead to
If successful, this could show that supervised exercise is safe and beneficial for people with cardiac amyloidosis, potentially improving their fitness and quality of life.
What could go wrong
This is a small pilot study with only 50 participants, so results may not apply to everyone. The intervention requires regular attendance, and some participants may not tolerate exercise well.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Amyloid Neuropathies, Familial amyloidosis heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC AMYLOIDOSIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sanger Heart and Vascular Institute

    RECRUITING

    Charlotte, North Carolina, 28204, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.